MASHINIi

Bicycle Therapeutics plc.

BCYC.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Bicycle Therapeutics plc is a biopharmaceutical company dedicated to discovering and developing a novel class of medicines based on its proprietary bicyclic peptide (Bicycle®) technology. Bicycle Therapeutics is developing Bicycle® molecules for indications in oncology. Bicycle Therapeutics plc is a...Show More

Ethical Profile

Mixed.

Bicycle Therapeutics presents a mixed ethical profile. While focused on developing novel therapies for cancers, the company conducts pre-clinical animal studies, a practice linked to conflicts with "Kind to Animals" values. Reports suggest potential tension over medicine access in developing countries due to patent strategies. Employee sentiment is 4.1/5, though some cite favoritism. CEO compensation hit $5,540,400 in 2023; median employee pay data is unavailable. Environmentally, they have a low ESG Risk Rating (15.8), My Green Lab certification, and an 18.5-ton waste reduction target. Data protection adheres to UK GDPR/CCPA and ISO27001 standards.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect40
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-40
-100100
No War, No Weapons10
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products-40
-100100

Better Health for All

0

No evidence available to assess Bicycle Therapeutics plc on Better Health for All.

Fair Money & Economic Opportunity

0

No evidence available to assess Bicycle Therapeutics plc on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

40

The company has an overall employee rating of 4.1 out of 5 stars on Glassdoor, with 77% of employees stating they would recommend working there.

1
The CEO has a 100% approval rating.
2
Employees rate compensation and benefits at 4.0 out of 5 stars, which improved by 2% over the last 12 months.
3
Work-life balance is also rated 4.0 out of 5 stars, while culture and values, and career opportunities are rated 3.7 out of 5 stars.
4

Fair Trade & Ethical Sourcing

0

No evidence available to assess Bicycle Therapeutics plc on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

No specific, concrete data points related to the 'Honest & Fair Business' ethical value were found in the provided article.

1
Therefore, no KPIs can be scored.

Kind to Animals

-40

Bicycle Therapeutics employs both in vitro (cell-based assays, Retrogenix binding screen) and in vivo (animal) methods for drug development, indicating that non-animal assays cover early-stage toxicity screens but are not exclusively used for complex endpoints.

1
The company conducts preclinical studies on animals, including mice, rats, hamsters, and cynomolgus monkeys.
2
Specific experiments involved N=4 or N=6 animals per group for mice and hamsters, and repeat dose toxicology studies were performed in rats and cynomolgus monkeys.
3
The company uses fetal bovine serum in cell culture media.
4
All animal procedures are performed according to guidelines approved by Institutional Animal Care and Use Committees (IACUC) and adhere to Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) standards, with some facilities being AAALAC accredited.
5
The company's policy is to conduct preclinical studies on animals to assess drug safety, which aligns with a policy that prohibits discretionary testing but allows legal mandates to override alternatives.
6

No War, No Weapons

10

Bicycle Therapeutics plc's core business is biopharmaceuticals, focused on oncology. Sustainalytics data indicates no significant involvement in military contracting, controversial weapons, or small arms.

1
This means the company derives 0% revenue from arms or defense contracts. Given its core business, it does not develop or sell dual-use products, nor does it have a dual-use portfolio to screen. The company has verified zero exposure to controversial weapons, as confirmed by a third-party assessment from Sustainalytics.
2
Its ethical red lines codify bans on all categories of conventional arms, and it demonstrates 100% compliance with these ethical standards in its core business operations. There are no defense assets to divest, and no applicable peace technology development in the context of military technology.

Planet-Friendly Business

0

The provided articles offer an overall ESG Risk Score of 16 (or 15.8) and an industry rank of 26 out of 847 in the Pharmaceuticals industry.

1
However, they explicitly state a lack of detailed information on specific sustainability metrics such as emissions, renewable energy, or water use.
2
No information on regulatory actions, violations, fines, or compliance issues is provided.
3
Consequently, no concrete data points are available to assess Bicycle Therapeutics plc against any of the specific Planet-Friendly Business KPIs in the rubric.

Respect for Cultures & Communities

0

No relevant data was found in the provided articles to assess Bicycle Therapeutics plc against the 'Respect for Cultures & Communities' value. Both articles indicated 404 errors, meaning no information could be extracted.

1

Safe & Smart Tech

0

The company experienced a phishing incident where email accounts were accessed by unauthorized third parties, but third-party investigations found no evidence of access or acquisition of any personal information.

1
All employees receive annual training on the Code of Business Conduct and Ethics, which defines standards for appropriate behavior.
2
Encryption of data is implemented, and encrypted channels are used for intragroup transfers outside the UK.
3
The company prohibits the use of confidential information for unauthorized purposes and states it does not sell user data to third parties.
4
Users have rights to access, rectify, erase, restrict processing, object to processing, and data portability under UK GDPR and CCPA.
5
Authentication technology is used, and vulnerability management, including risk and vulnerability assessments, is part of the company's policies.
6
Penetration testing is implemented.
7
The company's Privacy Notice was written with brevity and clarity, and privacy principles are integrated into the recruitment process.
8
Data is collected only as necessary for recruitment and retained for specific periods, such as no longer than twelve months for unsuccessful job applicants.
9
The company complies with UK GDPR and CCPA.
10
The company does not restrict personnel from communicating with governmental or law enforcement entities regarding possible violations of law or regulation.
11

Zero Waste & Sustainable Products

-40

Bicycle Therapeutics plc achieved a waste reduction of 22.7 tons in 2022 and set a waste reduction target of 18.5 tons for 2023.

1
The company's labs have achieved My Green Lab certification, and its Biology and Chemistry teams improved their sustainability scores from the previous year.
2
The company has an environmental compliance audit score of 92/100 and 67% of its suppliers are certified sustainable.
3

Own Bicycle Therapeutics plc?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.